¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Research communications in substance abuse."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • polydrug abuse
    ´ÙÁ¾¾à¹°³²¿ë, ¿©·¯¾à¹°³²¿ë
  • polysubstance abuse
    ´ÙÁ¾¹°Áú³²¿ë, ¿©·¯¹°Áú³²¿ë
  • spouse abuse
    ¹è¿ìÀÚÇдë
  • sexual abuse
    ¼ºÆøÇà, ¼ºÇдë, ¼º¹üÁË
  • voice abuse
    À½¼º³²¿ë, ¹ß¼º³²¿ë
  • antibacterial substance
    Ç×±Õ¹°Áú
  • antifungal substance
    Ç×Áø±Õ¹°Áú
  • carcinogenic substance
    ¹ß¾Ï¹°Áú
  • cortical substance
    °ÑÁú, ÇÇÁú
  • crystalline substance
    °áÁ¤¹°Áú
  • cement substance
    Á¢ÇÕÁú, ½Ã¸àÆ®¹°Áú
  • chromophil substance
    È£»ö¼Òü, »ö¼Òģȭ¹°Áú
  • depressor substance
    °¨¾Ð¹°Áú
  • ferromagnetic substance
    °­ÀÚ¼º¹°Áú
  • gelatinous substance
    Á©¶óƾ¹°Áú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • physical abuse
    ½ÅüÇдë
  • polydrug abuse
    º¹Çվ๰³²¿ë
  • polysubstance abuse
    º¹ÇÕ¹°Áú³²¿ë
  • sexual abuse
    ¼ºÆøÇà, ¼ºÇдë
  • spouse abuse
    ¹è¿ìÀÚÇдë
  • voice abuse
    À½¼º³²¿ë, ¹ß¼º³²¿ë
  • accelerans substance
    ÃËÁø¹°Áú
  • accessory food substance
    ºÎ¿µ¾ç¹°Áú
  • acrosomal substance
    ÷´Üü¹°Áú
  • agglutinable substance
    ÀÀÁý¼º¹°Áú
  • antibacterial substance
    Ç×±Õ¹°Áú
  • antifungal substance
    Ç×Áø±Õ¹°Áú
  • antiketogenic substance
    Ç×ÄÉÅæ»ý¼º¹°Áú
  • antithyroid substance
    Ç×¹æÆÐ»ù¹°Áú, Ç×°©»ó»ù¹°Áú
  • antiyeast substance
    Ç×È¿¸ð¹°Áú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Inducer substance
    À¯µµ¹°Áú(ë¯ÓôÚªòõ)
  • Inhibitor substance
    ¾ïÁ¦¹°Áú(åäð¤Úªòõ)
  • Kerry reducing substance test
    Äɸ®È¯¿ø¹°Áú½ÃÇè
  • Mullerian inhibiting substance
    ¹°·¯°ü ¾ïÁ¦¹°Áú
  • P substance
    P¹°Áú
  • SRS A : slow reacting substance A
    ¿¡½º¾Ë¿¡½º-¿¡ÀÌ.
  • accelerans substance
    ÃËÁø¹°Áú(õµòäÚªòõ).
  • accessory food substance
    ºÎ¿µ¾ç¹°(Üùç½å×Úª).
  • acrosomal substance
    ÷´Üü¹°Áú
  • agglutinable substance
    ÀÀÁý¼º ¹°Áú(ëêó¢àõÚªòõ).
  • anterior perforated substance
    ¾Õ°üÅëÁú
  • anterior pituitary-like substance
    ³úÇϼöü Àü¿±À¯»ç¹°Áú(¡­×¾ÞÄÚªòõ).
  • antibacterial substance
    Ç×±Õ¹°Áú.
  • antifungal substance
    Ç×Áø±Õ¼º ¹°Áú.
  • antifungal substance
    Ç×Áø±Õ¼º ¹°Áú.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • drug abuse
    ¾à¹° ³²¿ë
  • drug abuse
    ¾à¹°³²¿ë
  • drug abuse
    ¾à¹°³²¿ë(å·ÚªÕ½éÄ).
  • hallucinogen abuse
    ȯ°¢Á¦³²¿ë(ü³ÊÆð¥ÑúéÄ)
  • husband abuse
    ³²Æí Çдë
  • intravenous drug abuse
    Á¤¸Æ³» ¾à¹° ³²¿ë
  • narcotic abuse
  • opiate abuse
    ¾ÆÆíÁ¦³²¿ë
  • opioid abuse
  • phencyclidine abuse
    Ææ½ÎÀÌŬ¸®µò ³²¿ë(ÑúéÄ)
  • physical abuse
    ½ÅüÀû Çдë
  • polydrug abuse
    º¹Çվ๰³²¿ë
  • polysubstance abuse
    º¹ÇÕ¹°Áú³²¿ë
  • self abuse =masturbation, onanism
    ¼öÀ½(â¢ëâ), ÀÚÀ§(í»êÐ).
  • sexual abuse
    ¼ºÆøÇà
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Intercellular substance
    ¼¼Æ÷»çÀ̹°Áú
    [¿¾ ¿ë¾î] ½Ã¸àÆ®Áú¼¼Æ÷°£Áú
  • Lens substance
    ¼öÁ¤Ã¼¹°Áú
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼Áú
  • Neurosecretory substance
    ½Å°æºÐºñ¹°
    [¿¾ ¿ë¾î] ½Å°æºÐºñ¹°
  • Gelatinous substance
    ¾Æ±³Áú
    [¿¾ ¿ë¾î] ±³¾çÁú
  • Anterior perforated substance
    ¾Õ°üÅëÁú
    [¿¾ ¿ë¾î] ÀüÀ¯°øÁú
  • Central gelatinous substance
    Á߽ɾƱ³Áú
    [¿¾ ¿ë¾î] Á߽ɱ³¾çÁú
  • Central intermediate substance
    Áß½ÉÁß°£È¸»öÁú
    [¿¾ ¿ë¾î] Áß°£ÁúÁ߽ɺÎ
  • Central gray (substance)
    Áß½Éȸ»öÁú
    [¿¾ ¿ë¾î] Áß½Éȸ¹éÁú
  • Postacrosomal substance
    ÷´ÜüµÚ¹°Áú
    [¿¾ ¿ë¾î] ÷´ÜüÈŰÁú
  • Postacrosomal substance
    ÷´ÜüµÚ¹°Áú
    [¿¾ ¿ë¾î] ÷´ÜüÈÄÁú
  • Acrosomal substance
    ÷´Üü¹°Áú
    [¿¾ ¿ë¾î] ÷´Üü¹°Áú
  • Acrosomal substance
    ÷´Üü¹°Áú
    [¿¾ ¿ë¾î] ÷´ÜüÁú
  • Subacrosomal substance
    ÷´Üü¹Ø¹°Áú
    [¿¾ ¿ë¾î] ÷´ÜüÇϹ°Áú
  • Subacrosomal substance
    ÷´Üü¹Ø¹°Áú
    [¿¾ ¿ë¾î] ÷´ÜüÇÏÁú
  • Substance of synaptic cleft
    Æ´»õ¹°Áú
    [¿¾ ¿ë¾î] ¿­³»Áú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MIS management information system; medical information service; meiosis-inducing substance; minimally in...
BICC Biomedical Information Communications Center
HESCA Health Sciences Communications Association
LACN local area communications network
NDC National Data Communications; National Drug Code; Naval Dental Clinic; nondifferentiated cell
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DARP Drug Abuse Reporting Program
DATOS Drug Abuse Treatment Outcome Study
DAWN Drug Abuse Warning Network
IVDA Intravenous drug abuse
NHSDA National Household Survey of Drug Abuse
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • accessory food substance
    ºÎ¿µ¾ç¹°
  • accessory growth substance
    ¹ßÀ° º¸Á¶ ¹°Áú
    ¹ßÀ°À» Çϴµ¥ º¸Á¶µÇ´Â ¹°Áú.
  • agglutinable substance
    ÀÀÁý¼º ¹°Áú
  • anti-intercellular substance antibody
    Ç×¼¼Æ÷°£ ¹°Áú Ç×ü
  • ascending substance P
    »óÇà P ¹°Áú
  • bone inducing substance
    °ñ Çü¼º À¯µµ ÀÎÀÚ
  • bone substance
    °ñÁú
  • cement substance
    Á¢ÇÕ ¹°Áú
    µÎ °³ÀÇ Ç¥¸éÀ» °ß°íÇÏ°Ô Á¢ÇÕÇÏ´Â ¹°Áú.
  • coagualtion-active substance
    ÀÀ°í Ȱ¼º ¹°Áú
  • corrosive substance
    ºÎ½Ä ¹°Áú, ºÎ½Ä¼º ¹°Áú
  • cytotoxic substance
    ¼¼Æ÷ µ¶, ¼¼Æ÷µ¶¼Ò
    µ¿ÀǾî=cytotoxin.
  • endobiotic substance
    ³»»ýÀû ¹°Áú
  • ferromagnetic substance
    öÀÚ¼º ü, °­ÀÚ¼º ü
  • intercelluar substance
    ¼¼Æ÷°£ ¹°Áú
  • intercellular substance
    ¼¼Æ÷ °£Áú, ¼¼Æ÷°£ ¹°Áú
    ¼¼Æ÷¿Í ¼¼Æ÷ »çÀ̸¦ ä¿ì´Â ¹°Áú. ±âÁúÀ̶ó°íµµ ÇÑ´Ù. ÁÖµÈ ¼ººÐÀº È÷¾Ë¿ì·Ð»êÀ̳ª Äܵå·ÎÀÌÆ¾ Ȳ»ê µîÀÇ Á¡¾× ´Ù´çÀ» ÁÖ·ÎÇÏ´Â ´Ü¹éÁú ´Ù´çÀÌ´Ù. »À Á¶Á÷¿¡¼­´Â Ä®½· ¿°, ¸¶±×³×½· ¿°À» ¼¼Æ÷°£ ¹°Áú·Î¼­ ÇÔÀ¯Çϰí ÀÖ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
drug abuse Use of a drug for a reason other than which it was intended or in a manner or in quantities other than directed. Drug dependence is a compulsion to take a drug to produce a desired effect or prevent unpleasant effects when the drug is withheld. Risk factors for drug abuse include: low self esteem, inability to deal with stress and emotional instability. Juveniles use drugs due to peer pressure. Signs of drug use in children include: a change in friends or group, long absences from home, poor performance in school, seclusion, stealing, lying, criminal behaviour, deteriorating family relationships, signs of drug intoxication and changes in behaviour. Commonly abused drugs include narcotic analgesic agents, benzodiazepines, cocaine, amphetamines, barbiturates, marijuana, LSD and phencyclidine. Many labs now offer quick and inexpensive urine drug screening. Psychological counseling and parental support will be necessary in children with this problem.
(27 Sep 1997)
elder abuse Emotional, nutritional, or physical maltreatment of the older person generally by family members or by institutional personnel.
(12 Dec 1998)
Venereal Disease Research Laboratory <microbiology> A blood test used to diagnose syphilis.
Read as nonreactive or negative if you do not have syphilis. The Venereal Disease Research Laboratory can also be positive is cases of leprosy, malaria, mononucleosis, lupus, hepatitis A and pregnancy.
Positive Venereal Disease Research Laboratory tests are usually followed up by a more specific test (FTA antibodies).
(12 Jan 1998)
Medical Research Council <organisation> A UK Government funded body to promote the balanced development of medical and related biological research in the United Kingdom.
It organises national clinical trials for the assessment of new treatment protocols for leukaemia and some of the related diseases.
(05 Jan 1998)
research Careful, a diligent search, a close searching, studious inquiry or examination.
(18 Nov 1997)
research, controlled The first controlled clinical research was probably done in 1875 by the british naval surgeon james lind who, on board the hms salisbury, gave sailors with scurvy either oranges or lemons or cider or vinegar or nutmeg (or another treatment) and after just six days discovered that the citrus-consuming sailors had recovered from scury, until then the scourge of extended sea voyages, while the sailors who had been given the other treatments remained uncured.
(12 Dec 1998)
research design A plan for collecting and utilizing data so that desired information can be obtained with sufficient precision or so that an hypothesis can be tested properly.
(12 Dec 1998)
research personnel Those individuals engaged in research.
(12 Dec 1998)
research support Financial support of research activities.
(12 Dec 1998)
peer review, research The evaluation by experts of the quality and pertinence of research or research proposals of other experts in the same field. Peer review is used by editors in deciding which submissions warrant publication, by granting agencies to determine which proposals should be funded, and by academic institutions in tenure decisions.
(12 Dec 1998)
clinical nursing research Research carried out by nurses in the clinical setting and designed to provide information that will help improve patient care. Other professional staff may also participate in the research.
(12 Dec 1998)
clinical research trials Evaluating the safety and effectiveness of medications or medical devices by monitoring their effects on large groups of people. Clinical medical trials sponsored by the U. S. Government are listed on a web site of the National Institutes of Health (NIH). The NIH Clinical Centre intends to make details of current clinical research studies for various diseases available over the Internet to increase opportunities for patients and physicians to participate in clinical investigations.
(12 Dec 1998)
controlled thermonuclear research General label for research on controlled thermonuclear fusion reactions.
(09 Oct 1997)
health outcomes research The measurement of the value of a particular course of therapy. Health outcomes research is based on the principle that every clinical intervention produces a change in the health status of a patient and that change can be measured.
(12 Dec 1998)
health services research The integration of epidemiologic, sociological, economic, and other analytic sciences in the study of health services. Health services research is usually concerned with relationships between need, demand, supply, use, and outcome of health services. The aim of the research is evaluation, particularly in terms of structure, process, output, and outcome.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • market research
    (Á¦Ç°À» ¸ÅÃâÇϱâ ÀüÀÇ) ½ÃÀå Á¶»ç
  • market research
    ½ÃÀå Á¶»ç (¾î¶² »óǰÀÇ ¼ö¿ä¸¦ À§ÇÑ »çÀü Á¶»ç)
  • marketing research
    ½ÃÀå Á¶»ç;½ÃÀå ºÐ¼®
  • motivational research
    µ¿±â Á¶»ç
  • operations research
    ±â¾÷ °æ¿µ»óÀÇ °úÇÐÀû Á¶»ç ¿¬±¸;ÀÛÀü ¿¬±¸
  • research
    (Çмú)¿¬±¸;°úÇÐÀû ޱ¸;ÇмúÁ¶»ç;(½ÅÁßÇÑ)¼ö»ö;ޱ¸;Á¶»ç;¿¬±¸ ´É·Â;¿¬±¸½É;¿¬±¸ÇÏ´Ù;Á¶»çÇÏ´Ù;~able
  • research and development
    ¿¬±¸¿Í °³¹ß
  • research laboratory(institute)
    ¿¬±¸¼Ò
  • research library
    ¿¬±¸ µµ¼­°ü ´Â
  • research paper
    ¿¬±¸ ³í¹®;(ÇлýÀÇ)Çб⸻ ¸®Æ÷Æ®
  • research professor
    ¿¬±¸ ±³¼ö(´ëÇÐ µî¿¡¼­ ÀÚÀ¯·ÎÀÌ ¿¬±¸¿¡ ¸ôµÎÇÒ ¼ö ÀÖ´Â ±³¼ö)
  • research reactor
    ¿¬±¸¿ë ¿øÀÚ·Î
  • research submersible
    ½ÉÇØ Àá¼ö Á¶»ç¼±
  • research work
    (Çмú»óÀÇ)¿¬±¸;Á¶»ç
  • research worker
    =RESEARCHER
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á